OnabotulinumtoxinA Dose-Ranging Study for Hyperdynamic Perioral Lines

被引:24
|
作者
Cohen, Joel L. [1 ,2 ]
Dayan, Steven H. [3 ,4 ]
Cox, Sue Ellen [5 ,6 ]
Yalamanchili, Ramana [7 ]
Tardie, Greg [7 ]
机构
[1] AboutSkin Dermatol & DermSurg, Englewood, CO 80113 USA
[2] Univ Colorado, Dept Dermatol, Denver, CO 80202 USA
[3] Univ Illinois, Dept Otolaryngol Head & Neck Surg, Chicago, IL USA
[4] Chicago Ctr Facial Plast Surg, Chicago, IL USA
[5] Univ N Carolina, Sch Med, Dept Dermatol, Chapel Hill, NC 27514 USA
[6] Aesthet Solut, Chapel Hill, NC USA
[7] SCI Sci Commun & Informat, Parsippany, NJ USA
关键词
TOXIN TYPE-A; ACID DERMAL FILLERS; SEVERE GLABELLAR RHYTIDES; LOWER FACIAL REJUVENATION; PARALLEL-GROUP; DOUBLE-BLIND; CONSENSUS RECOMMENDATIONS; 24-MG/ML SMOOTH; FEMALE SUBJECTS; COHESIVE GEL;
D O I
10.1111/j.1524-4725.2012.02456.x
中图分类号
R75 [皮肤病学与性病学];
学科分类号
100206 ;
摘要
Background Few dosing data on onabotulinumtoxinA to treat hyperdynamic perioral lines (POLs) are available. Studying onabotulinumtoxinA in controlled settings is beneficial to treating a hyperfunctional orbicularis oris. Objective To compare the dose-response relationship of two doses of onabotulinumtoxinA in hyperdynamic POLs. Methods Female subjects (N similar to=similar to 60) received injections of onabotulinumtoxinA at four sites totaling 7.5 similar to U or 12.0 similar to U. Subjects returned at weeks 2, 4, 8, 12, 16, and 20. POL severity and total lip satisfaction (TLS) were assessed at all visits. Results Investigator-assessed POL severity was reduced through week 20 for 12.0 similar to U (p similar to<similar to.01). POL reduction for 7.5 similar to U persisted until week 16 (p similar to<similar to.05). Responder rates did not differ until week 12 (12.0 similar to U, 77%; 7.5 similar to U, 36%; p similar to=similar to.003). Subject-assessed TLS was improved (p similar to<similar to.05) at all time points for both groups except at week 20 (12.0 similar to U; p similar to=similar to.06). Most adverse events (AEs) were mild to moderate in severity and typical for onabotulinumtoxinA treatment in the lips, and the incidence was dose-dependent. Conclusion OnabotulinumtoxinA provides significant reductions in POL severity and high levels of subject satisfaction. Lack of dose response and fewer AEs suggest that treatment of hyperdynamic POLs with 7.5 similar to U appears adequate for up to 16 similar to weeks.
引用
收藏
页码:1497 / 1505
页数:9
相关论文
共 50 条
  • [31] A Simulation Study to Compare New Adaptive Dose-Ranging Designs
    Dragalin, Vladimir
    Bornkamp, Bjoern
    Bretz, Frank
    Miller, Frank
    Padmanabhan, S. Krishna
    Patel, Nitin
    Perevozskaya, Inna
    Pinheiro, Jose
    Smith, Jonathan R.
    STATISTICS IN BIOPHARMACEUTICAL RESEARCH, 2010, 2 (04): : 487 - 512
  • [32] Oxcarbazepine in painful diabetic neuropathy: results of a dose-ranging study
    Beydoun, A
    Shaibani, A
    Hopwood, M
    Wan, Y
    ACTA NEUROLOGICA SCANDINAVICA, 2006, 113 (06): : 395 - 404
  • [33] A Randomized Double-blind Placebo-controlled Phase 2 Dose-ranging Study of OnabotulinumtoxinA in Men with Benign Prostatic Hyperplasia
    Marberger, Michael
    Chartier-Kastler, Emmanuel
    Egerdie, Blair
    Lee, Kyu-Sung
    Grosse, Joachim
    Bugarin, Denise
    Zhou, Jihao
    Patel, Anand
    Haag-Molkenteller, Cornelia
    EUROPEAN UROLOGY, 2013, 63 (03) : 496 - 503
  • [34] DOSE-RANGING STUDIES OF CLONAZEPAM IN MAN
    HOLLISTER, LE
    PSYCHOPHARMACOLOGY COMMUNICATIONS, 1975, 1 (01) : 89 - 92
  • [35] A dose-ranging study of bromfenac sodium in oral surgery pain
    Hersh, EV
    Cooper, SA
    Levin, LM
    Betts, NJ
    Wedell, D
    Lamp, C
    Wajdula, J
    ORAL SURGERY ORAL MEDICINE ORAL PATHOLOGY ORAL RADIOLOGY AND ENDODONTOLOGY, 1998, 86 (01): : 36 - 41
  • [36] Efficacy and tolerability of sibutramine in obese patients: a dose-ranging study
    Hanotin, C
    Thomas, F
    Jones, SP
    Leutenegger, E
    Drouin, P
    INTERNATIONAL JOURNAL OF OBESITY, 1998, 22 (01) : 32 - 38
  • [37] A DOSE-RANGING STUDY TO EVALUATE THE CARDIOSELECTIVITY OF ATENOLOL IN NORMAL SUBJECTS
    LIPWORTH, BJ
    MCFARLANE, LC
    COUTIE, W
    MCDEVITT, DG
    BRITISH JOURNAL OF CLINICAL PHARMACOLOGY, 1989, 27 (05) : P684 - P685
  • [38] A Dose-Ranging Study of Diacerein in Patients With Type 2 Diabetes
    Brown, Carl O.
    Lu, Weishu
    Lin, Emily
    Chen, Calvin
    DIABETES, 2013, 62 : A272 - A273
  • [39] FLUTOPRAZEPAM IN THE TREATMENT OF GENERALIZED ANXIETY DISORDERS - A DOSE-RANGING STUDY
    REALINI, R
    MASCETTI, R
    MACCIOCCHI, A
    RIEBENFELD, D
    CURRENT THERAPEUTIC RESEARCH-CLINICAL AND EXPERIMENTAL, 1990, 47 (05): : 860 - 868
  • [40] Efficacy and tolerability of sibutramine in obese patients: a dose-ranging study
    C Hanotin
    F Thomas
    SP Jones
    E Leutenegger
    P Drouin
    International Journal of Obesity, 1998, 22 : 32 - 38